Rare cancers make up 25% to 30% of U.S. cancer diagnoses, but tools are built for common tumors. A new open-source AI pipeline matched 30% of tested sarcoma patients to a drug option for about $1.17 each.
@cureusmedical.bsky.social
@cureusmedical.bsky.socialRare cancers make up 25% to 30% of U.S. cancer diagnoses, but tools are built for common tumors. A new open-source AI pipeline matched 30% of tested sarcoma patients to a drug option for about $1.17 each.
@4040rec.bsky.social
@arcportal.org.auCongratulations to ARCP authors AProf Bryan Chan, @ProfClareScott, and Dr Cassie Turner on their publication exploring 42 years of data on sinonasal undifferentiated carcinoma (SNUC) in Queensland.
@nordrare.bsky.socialThis #RareCancerDay, NORD is sharing findings from a survey of oncologists we conducted with @medliveofficial.bsky.social.
What we found: 1 in 2 oncologists don't feel confident recognizing a rare #cancer.
Read our full findings: bit.ly/4cXKhgn
@pheopara.bsky.socialOn #RareCancerDay, we’re raising awareness of pheochromocytoma and paraganglioma (PPGL). 💚
Share this post to help make rare cancers like PPGL more visible.
@pheopara.bsky.socialOn #RareCancerDay, we stand with everyone affected by rare cancers and the PPGL community working toward better answers, knowledgeable care, stronger support, and greater awareness.
Together, we can make rare more visible.
#PheoParaAlliance #PPGL #RareCancer #Pheochromocytoma #Paraganglioma
@liposarcomasupport.bsky.socialThe STC-15 (a METTL3 inhibitor) Phase 2 monotherapy trial is currently recruiting for #DDLPS patients. Learn more: clinicaltrials.gov/study/NCT069... #Liposarcoma #Sarcoma #RareCancer #METTL3Sinhibitor
